Literature DB >> 8812683

What Models of Granulomatous Inflammation Provide the Immunologist

.   

Abstract

Granulomas usually serve to protect the host from the spread of persistent microorganisms or other enduring injurious substances. They are complex inflammatory reactions that use many immune mechanisms to control the inciting nudis. These lesions can persist for weeks, months, or even years. Thus, understanding the mechanisms that enhance, diminish, or modulate granulomas could aid in the treatment of many diseases. Moreover, experimental animal models of granulomatous inflammation allow sophisticated investigation of some disease processes not possible using human subjects. Granulomatous inflammations are chronic, composed of activated leukocytes that are selected for deposition at the site of injury. They use various effector mechanisms, delicately balanced by many immunoregulatory circuits. Under some experimental conditions, granulomas can be isolated readily from host tissue and subjected to sophisticated immunological analysis. Therefore, it is possible to dissect the actual, local control mechanisms that govern the granulomatous response. Lesions learned studying granulomas are applicable to other types of inflammation, since granulomas use immunoregulatory networks and soluble cytokines common to many inflammatory states. Using these experimental models, it is readily apparent that studies utilizing splenocytes or peripheral blood leukocytes may not reveal the true, dominant immunoregulatory mechanisms employed at sites of active inflammation. The leukocytes of spleens and blood are a mixture of cells in various stages of activation, many of which are not destined to participate in a selective immune response. Also, granulomas are sustained inflammatory reactions permitting analysis of the unique features of chronic maintenance, as opposed to acute phase inflammation.

Entities:  

Year:  1996        PMID: 8812683     DOI: 10.1006/meth.1996.0035

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  3 in total

1.  Angiotensinogen and transforming growth factor beta1: novel genes in the pathogenesis of Crohn's disease.

Authors:  G E Hume; E V Fowler; D Lincoln; R Eri; D Templeton; T H Florin; J A Cavanaugh; G L Radford-Smith
Journal:  J Med Genet       Date:  2006-10       Impact factor: 6.318

2.  CD43 regulates Th2 differentiation and inflammation.

Authors:  Judy L Cannon; Amélie Collins; Purvi D Mody; Diwaker Balachandran; Kammi J Henriksen; Cassandra E Smith; Jiankun Tong; Bryan S Clay; Stephen D Miller; Anne I Sperling
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

3.  Protective effector memory CD4 T cells depend on ICOS for survival.

Authors:  Tamson V Moore; Bryan S Clay; Caroline M Ferreira; Jesse W Williams; Magdalena Rogozinska; Judy L Cannon; Rebecca A Shilling; Amanda L Marzo; Anne I Sperling
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.